Brooks Laboratories Ltd (BROOKS)
₹62.35
Brooks Laboratories Ltd Performance
₹61.25
Day's Price Range
₹66.5
₹57.9
52-Week Price Range
₹143.45
| Returns % | |
| 1 Month Return | -33.94 % |
| 3 Month Return | -41.67 % |
| 1 Year Return | -13.1 % |
Brooks Laboratories Ltd Valuation
Brooks Laboratories Ltd in the last 5 years
Lowest (-21.23x)
September 15, 2021
Today (-6.04x)
March 29, 2023
Highest (-5.82x)
March 20, 2023
LowHigh
-6.04x
Price to Earnings TTM Ratio
Insights on Brooks Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, BROOKS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 66.41% of holdings in Dec 2022 quarter
- NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 8.4% return, outperforming this stock by 21.5%
NEGATIVE IMPACTPrice Dip
In the last 1 month, BROOKS stock has moved down by -33.7%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -4.68 Cr → -5.02 Cr (in ₹), with an average decrease of 7.3% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 18.48 Cr → 15.76 Cr (in ₹), with an average decrease of 14.7% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 33.59% to 33.52% in Dec 2022 quarter
Brooks Laboratories Ltd Peer Comparison
Brooks Laboratories Ltd Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 66.41% | 0.00 | |
| Foreign Institutions | 0% | 0.00 | |
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 33.52% | ||
| Others | 0.06% | 0.00 |
Corporate Announcements
Brooks Laboratories Ltd Earnings Results
Brooks Laboratories Ltd’s net profit jumped 24.05% since last year same period to ₹-5.02Cr in the Q3 2022-2023. On a quarterly growth basis, Brooks Laboratories Ltd has generated -7.26% fall in its net profits since last 3-months.
Read More about Earnings Results
Brooks Laboratories Ltd Company Information
Brooks Laboratories Ltd is a pharmaceutical manufacturing company working on contract basis. The company has manufacturing plants at Baddi Himachal Pradesh and Vadodara Gujarat. Both the units are cGMP compliant in conformity with national and international standards. The Vadodara facility of the company has been approved by European Medicine agency. The company has a wide range of products catering to critical care segment in Parental Section like Beta Lactam Cephalosporin General Dry powder Injectables Ampoules and Liquid vials Dry Syrups and Tablets etc. Their product portfolio presently comprises of 28 Injectables 19 Tablets and 2 Dry Syrups which are marketed domestically.The companys manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes. At Baddi they manufacture wide range of products under the formulation segment for various top notch companies of India.The companys major clients are companies like Zydus Cadila Aristo Pharmaceuticals Pvt Ltd FDC Ltd Nectar Lifesciences Ltd Sanat Products Ltd Hetero Healthcare Ltd Medley Pharmaceuticals Wockhardt Ltd Parental Drugs Chanderbhagat Pharma and Alembic Ltd etc. Their major suppliers of raw materials are Rajasthan Antibiotics Ltd Aurobindo Pharma Ltd DSM Anti Infectives Ltd and Qilu Pharmaceutical Company Ltd.Brooks Laboratories Ltd was incorporated on January 23 2002. The company was initially promoted for manufacturing latest molecules in Injectables tablets and dry syrups for the domestic customers. In the year 2006 the company set up a facility for manufacturing Tablets Dry Syrup and Injectables which was supported by a research and development RD centre at Baddi Himachal Pradesh. In May 2006 they started their operations and in June 3 2006 they commenced commercial production.In October 2006 the company obtained Import license from Drugs Controller General of India under the Drugs Act 1940 and Drugs Rules. In August 2007 they received an AS/NZS ISO 9001:2000 Certificate from SAI Global Certification Services Pty Ltd Australia. In April 2008 the company took over some of the assets of Brooks Pharmaceuticals a partnership firm of the promoters Atul Ranchal Rajesh Mahajan.In April 2010 the manufacturing facility at Baddi was certified as WHO GMP compliant by Department of Health Family Welfare HP. In July 2010 the company received an ISO 9001:2008 Certificate from UKAS Quality Management URS IAF.In August 2011 Brooks Laboratories raised Rs. 63 crore from the public through IPO. The shares of the company got listed on the stock exchanges with effect from 5 September 2011.During the financial year ended 31 March 2014 the company operated the Baddi plant at 100 capacity. During the financial year ended 31 March 2015 the company operated the Baddi plant at 100 capacity. During the financial year ended 31 March 2016 the company operated the Baddi plant at 92 capacity.On 7 March 2017 Brooks Laboratories world class dedicated carbapenem facility in Vadodara Plant started manufacturing activity. Brooks Management decided to upgrade the facility in line with cGMP in Baddi plant. Since it was a running unit the company decided to upgrade the Baddi facility in steps. As a first step the company upgraded one injectable manufacturing line which started commercial production in November 2016. The company operated the Baddi plant at 92 capacity during the year under review.The upgradation of injectable line in Baddi facility was carried out for 3 months from June 2017 whereby production in injectable line was affected upgradation was completed and production started from September onwards in Baddi facility. During the year ended 31 March 2018 the company operated the Baddi plant at 90 capacity except for 3 months from June to August due to upgradation of injectable facility in Baddi.The company commenced production in August 2017 in new renovated building at Baddi plant with almost double the capacity of previous line.
Brooks Laboratories Ltd Share Price: ₹62.35 per share as on 31 Mar, 2023 04:01 PM
Brooks Laboratories Ltd Market Capitalisation: ₹253.57Cr as of today
Brooks Laboratories Ltd Revenue: ₹15.76Cr as on December 2022 (Q4 22)
Brooks Laboratories Ltd Net Profit: ₹-5.02Cr as on December 2022 (Q4 22)
Brooks Laboratories Ltd Listing date: 09 May, 2011
Brooks Laboratories Ltd Share Price: ₹62.35 per share as on 31 Mar, 2023 04:01 PM
Brooks Laboratories Ltd Market Capitalisation: ₹253.57Cr as of today
Brooks Laboratories Ltd Revenue: ₹15.76Cr as on December 2022 (Q4 22)
Brooks Laboratories Ltd Net Profit: ₹-5.02Cr as on December 2022 (Q4 22)
Brooks Laboratories Ltd Listing date: 09 May, 2011
| Organisation | Brooks Laboratories Ltd |
| Headquarters | Solan |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Frequently Asked Questions
Brooks Laboratories Ltd(BROOKS) share price today is ₹62.35 (last updated 31 Mar, 2023 at 04:01 PM)
- Today’s highest price of Brooks Laboratories Ltd(BROOKS) is ₹66.50.
- Today’s lowest price of Brooks Laboratories Ltd(BROOKS) is ₹61.25.
- (last updated 31 Mar, 2023 at 04:01 PM)
Today’s traded volume of Brooks Laboratories Ltd(BROOKS) is 223166.
Today’s market capitalisation of Brooks Laboratories Ltd(BROOKS) is ₹253.57Cr.
| Brooks Laboratories Ltd(BROOKS) | Price |
|---|---|
| 52 Week High | ₹143.45 |
| 52 Week Low | ₹57.90 |
Brooks Laboratories Ltd(BROOKS) share price is ₹62.35 (last updated 31 Mar, 2023 at 04:01 PM). It is down -56.54% from its 52 Week High price of ₹143.45
Brooks Laboratories Ltd(BROOKS) share price is ₹62.35 (last updated 31 Mar, 2023 at 04:01 PM). It is up 7.69% from its 52 Week Low price of ₹57.90
| Brooks Laboratories Ltd(BROOKS) | Returns (%) |
|---|---|
| 1 Day Returns | -1.58% |
| 1 Month Returns | -33.94% |
| 1 Year Returns | -13.10% |
| 3 Year Returns | 315.41% |
| 5 Year Returns | -7.93% |
Brooks Laboratories Ltd(BROOKS) share price is ₹62.35 and its price to earning (PE) is -6.04. A high PE ratio indicates that a share price is overvalued, or investors are expecting a high growth rate in the future.